Last reviewed · How we verify
Orthostatic hypotension — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Northera | DROXIDOPA | Lundbeck Na Ltd | Catecholamine | Muscarinic acetylcholine receptor M1 | 2014-01-01 | |
| Northera | Northera | The Cooper Health System | Muscarinic acetylcholine receptor M1, Adrenergic receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Lundbeck Na Ltd · 1 drug in Orthostatic hypotension
- The Cooper Health System · 1 drug in Orthostatic hypotension
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Orthostatic hypotension:
- Orthostatic hypotension treatment updates — RSS
- Orthostatic hypotension treatment updates — Atom
- Orthostatic hypotension treatment updates — JSON
Cite this brief
Drug Landscape (2026). Orthostatic hypotension — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/orthostatic-hypotension. Accessed 2026-06-10.
Related
- Orthostatic hypotension full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing